Abstract | BACKGROUND: Treatment options for children and adolescents with migraine are limited. This study evaluated rizatriptan for the acute treatment of migraine in children and adolescents. METHODS: Randomized, double-blind, placebo-controlled, parallel-group trial in migraineurs 6-17 years old with unsatisfactory response to nonsteroidal anti-inflammatory drugs or acetaminophen/ paracetamol. The trial included a double-blind run-in with weight-based rizatriptan dosing (5 mg for < 40 kg, 10 mg for ≥ 40 kg). In the Stage 1 run-in, patients were randomized in a ratio of 20:1 placebo: rizatriptan and were instructed to treat within 30 minutes of a moderate/severe migraine. Patients with mild/no pain after 15 minutes of treatment (responders) took no further study medication, whereas patients with moderate/severe pain (non-responders) proceeded to take study medication in Stage 2. Non-responders who received placebo in Stage 1 were randomized 1:1 to rizatriptan:placebo, whereas non-responders who received rizatriptan in Stage 1 were allocated to placebo in Stage 2. The primary efficacy endpoint was pain freedom at 2 hours after Stage 2 dose in 12-17-year-olds. RESULTS: A higher proportion of 12-17-year-olds on rizatriptan had pain freedom at 2 hours compared with those on placebo: 87/284 (30.6%) versus 63/286 (22.0%), odds ratio = 1.55 [95% CI: 1.06 to 2.26], p = 0.025. Adverse events within 14 days of dose in 12-17-year-olds were similar for rizatriptan and placebo. The pattern of findings was similar in 6-17-year-olds. CONCLUSION:
Rizatriptan demonstrated a statistically significant improvement over placebo in eliminating pain and was generally well tolerated in migraineurs aged 12-17 and 6-17 years. TRIAL REGISTRATION: ClinicalTrials.gov NCT01001234.
|
Authors | Tony W Ho, Eric Pearlman, Donald Lewis, Mirja Hämäläinen, Kathryn Connor, David Michelson, Ying Zhang, Christopher Assaid, Lyn Harper Mozley, Nancy Strickler, Robert Bachman, Erin Mahoney, Christopher Lines, David J Hewitt, Rizatriptan Protocol 082 Pediatric Migraine Study Group |
Journal | Cephalalgia : an international journal of headache
(Cephalalgia)
Vol. 32
Issue 10
Pg. 750-65
(Jul 2012)
ISSN: 1468-2982 [Electronic] England |
PMID | 22711898
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Serotonin Receptor Agonists
- Triazoles
- Tryptamines
- rizatriptan
|
Topics |
- Adolescent
- Child
- Double-Blind Method
- Female
- Humans
- Male
- Migraine Disorders
(drug therapy)
- Serotonin Receptor Agonists
(therapeutic use)
- Treatment Outcome
- Triazoles
(therapeutic use)
- Tryptamines
(therapeutic use)
|